Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.9244
0.02412.68%
Last update: Jun 17, 11:24 AM
Quince Therapeutics Inc Analyst Ratings
QNCXNASDAQ
Quince Therapeutics Analyst Ratings and Price Targets | NASDAQ:QNCX | Benzinga
Quince Therapeutics Inc has a consensus price target of $9.33 based on the ratings of 8 analysts. The high is $12 issued by EF Hutton on October 22, 2024. The low is $6 issued by Maxim Group on November 7, 2024. The 3 most-recent analyst ratings were released by D. Boral Capital on January 29, 2026, December 15, 2025, and November 13, 2025, respectively. With an average price target of $4.67 between D. Boral Capital, there's an implied 404.83% upside for Quince Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
Oppenheimer
Brookline Capital
Maxim Group
Rodman & Renshaw
1calculated from analyst ratings
Analyst Ratings for Quince Therapeutics
Loading calendar...
FAQ
What is the target price for Quince Therapeutics (QNCX) stock?
The latest price target for Quince Therapeutics (NASDAQ:QNCX) was reported by Citizens on January 30, 2026. The analyst firm set a price target for $0.00 expecting QNCX to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Quince Therapeutics (QNCX)?
The latest analyst rating for Quince Therapeutics (NASDAQ:QNCX) was provided by Citizens, and Quince Therapeutics downgraded their market perform rating.
When was the last upgrade for Quince Therapeutics (QNCX)?
There is no last upgrade for Quince Therapeutics
When was the last downgrade for Quince Therapeutics (QNCX)?
The last downgrade for Quince Therapeutics Inc happened on January 30, 2026 when Citizens changed their price target from N/A to N/A for Quince Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Quince Therapeutics (QNCX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Quince Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Quince Therapeutics was filed on January 30, 2026 so you should expect the next rating to be made available sometime around January 30, 2027.
Is the Analyst Rating Quince Therapeutics (QNCX) correct?
While ratings are subjective and will change, the latest Quince Therapeutics (QNCX) rating was a downgraded with a price target of $0.00 to $0.00. The current price Quince Therapeutics (QNCX) is trading at is $0.92, which is out of the analyst’s predicted range.
